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Edited by Barry HalliwellAbstract Protein kinase CKII (CKII) plays a critical role in
cell growth and proliferation. In this study, we examine how
CKII activity is regulated during cellular senescence. Our results
demonstrate that CKII activity apparently decreases during both
replicative and H2O2-induced senescence in human diploid ﬁbro-
blast IMR-90 cells. The mRNA and protein levels of CKIIa de-
creases signiﬁcantly during replicative and H2O2-induced
senescence, while only slight reduction in those of CKIIb is ob-
served during replicative senescence. Treatment of IMR-90 cells
with CKII inhibitors 5,6-dichloro-1-b-D-ribofuranosylbenzimi-
dazole and apigenin led cells to acquire a senescent phenotype
as judged by the senescence-associated b-galactosidase marker
and overexpression of p53 and p21Waf-1. Knockdown of CKIIa
in IMR-90 cells by RNA interference also dramatically induced
the senescent phenotype. In parallel, CKII activity was transcrip-
tional downregulated in rat liver and testis with advancing age.
Taken together, these results suggest that downregulation of
CKII activity is tightly associated not only with cellular senes-
cence but also with organism aging.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Protein kinase CKII (CKII) (formerly known as casein ki-
nase II) is a ubiquitous and highly conserved protein serine/
threonine kinase, which is found in all eukaryotes examined
and in various subcellular compartments [1–3]. The holoen-
zyme of CKII is a heterotetramer, composed of two catalytic
(a and/or a 0) and two regulatory (b) subunits. The a and a 0
subunits are diﬀerent gene products and exhibit the catalytic
activity of the enzyme. The b subunit is thought to be a regu-
latory subunit that modulates the catalytic activity of a or a 0Abbreviations: CKII, protein kinase CKII (also known as casein kinase
II); DRB, 5,6-dichloro-1-b-D-ribofuranosylbenzimidazole; PBS, phos-
phate-buﬀered saline; PDL, population doubling level; PCR, poly-
merase chain reaction; SA-b-gal, senescent-associated b-galactosidase;
SDS, sodium dodecyl sulfate; siRNA, small-interfering RNA
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doi:10.1016/j.febslet.2006.01.028subunits and also mediates tetramer formation and substrate
recognition [4–6]. CKII is a second messenger-independent en-
zyme. Crystal structure of the catalytic subunit a has con-
ﬁrmed the constitutively active nature of CKII [7]. The
catalytic activity of CKII is inhibited strongly by 5,6-di-
chloro-1-b-D-ribofuranosylbenzimidazole (DRB) and apigenin
and stimulated by polybasic compounds such as polyamines
and spermine [1–3,8,9].
CKII plays a signiﬁcant role in the control of cell prolifera-
tion and transformation [1–3]. CKII is known to catalyze the
phosphorylation of a broad spectrum of substrates, which
are involved in cell growth and proliferation, including
DNA-binding proteins, nuclear oncoproteins, and transcrip-
tion factors [1–3]. The expression level of CKII is greatly en-
hanced in a variety of tumor or leukemic cells [10–13].
Overexpression of CKIIa in the T cells of transgenic mice re-
sults in a high predisposition for lymphoma formation, and
coexpression with c-Myc results in the rapid development of
leukemia [14]. Overexpression of CKIIa or CKIIa 0 exhibits
cooperativity with Ras in the transformation of rat embryo
ﬁbroblasts and Balb/c 3T3 cells [15]. Microinjection of anti-
bodies directed against either CKIIa or CKIIb inhibits cell cy-
cle progression in response to serum stimulation in human
IMR-90 cells [16–18]. An important role of CKII in cell divi-
sion cycle control has also been demonstrated in the yeast Sac-
charomyces cerevisiae. The analysis using temperature-sensitive
mutants for the CKII gene has shown that CKII is required for
cell cycle progression in both G1 and G2/M phases of the cell
cycle [19]. These observations suggest that CKII plays a signif-
icant role in cell proliferation and cell cycle.
Normal primary cells withdraw from the cell division cycle
after a variable number of cell divisions and enter an irrevers-
ible growth arrest state, designated replicative senescence or,
more generally, cellular senescence [20]. Cellular senescence
can also be induced by oxidative stress, DNA damage, histone
deacetylase inhibitor, and expression of active form of onco-
proteins such as Ras and Raf [21–25]. In the state of senes-
cence, cells become enlarged, acquire a ﬂattened
morphology, and express several senescence-associated mark-
ers, including senescent-associated b-galactosidase (SA-b-
gal), p53, and cyclin-dependent kinase inhibitors p21Waf-1
and p16Ink4a [24,26–29].
In the present study, we show evidence that CKII activity is
downregulated at transcription level in both senescent human
lung ﬁbroblast IMR-90 cells and aged rat tissues. We ﬁnd that
CKII inhibition in IMR-90 cells by CKII inhibitors orblished by Elsevier B.V. All rights reserved.
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ture senescence of the cells. To our knowledge, this is the ﬁrst
paper reporting transcriptional downregulation of CKII dur-
ing aging.Fig. 1. Decrease in CKII activity in IMR-90 cells during replicative
senescence. (A) After serial passages, IMR-90 cells of PDL 30, 44, or
56 were obtained. After ﬁxing in 2% formaldehyde/0.2% glutaralde-
hyde in PBS, cells were stained with 1 mg/ml 5-bromo-4-chloro-3-
indolyl b-D-galactoside as described in Section 2. The percentage of
positively stained cells was measured. (B) Lysates from IMR-90 cells of
PDL 30, 44, or 56 were utilized in kinase assays using the speciﬁc CKII
substrate peptide (RRREEETEEE). The 32P incorporation in the
substrate peptide was measured by scintillation counting. The results
represent two independent experiments done in duplicate. Results are
shown as the mean value ± S.D.2. Materials and methods
2.1. Cell culture and rat tissues
Human diploid ﬁbroblast IMR-90 cells were obtained from ATCC
(Manassas, VA) at a population doubling level (PDL) of 24. Cells were
cultured in Dulbecco’s modiﬁed Eagle’s medium (DMEM) containing
10% (v/v) fetal bovine serum (FBS) under a humidiﬁed atmosphere of
5% (v/v) CO2 at 37 C. The number of population doublings (PD) was
calculated from PD = log(Nf/Ni)/log2, where Nf is the ﬁnal cell number
and Ni is the initial number of seeded cells. For premature senescence,
cells were exposed for 2 h to several concentration of H2O2 diluted in
DMEM containing 10% FBS. The cells were washed with ice-cold
phosphate-buﬀered saline (PBS) and then given fresh medium for 4
days prior to harvest or staining.
Fischer 344 male rats were housed in the animal facility under path-
ogen-free conditions. Rats were sacriﬁced by decapitation, and liver
and testis were removed and washed in ice-cold PBS.
2.2. SA-b-gal activity assay
SA-b-gal activity was measured as described previously [27] with
minor modiﬁcations. Cells in sub-conﬂuent cultures were washed with
PBS, ﬁxed in 3% (v/v) formaldehyde in PBS for 10 min at room tem-
perature, and then incubated with a stain solution containing 1 mg/
ml 5-bromo-4-chloro-3-indolyl b-D-galactoside, 40 mM citric acid–so-
dium phosphate (pH 6.0), 5 mM potassium ferricyanide, 5 mM potas-
sium ferrocyanide, 150 mM NaCl, and 2 mMMgCl2 for 24 h at 37 C.
The number of blue-stained cells was counted in at least 10 ﬁelds at
400· magniﬁcation, and expressed as percentage of positive cells.
2.3. Preparation of cell extract
For immuno-blotting, IMR-90 cells in 60 mm-dishes were washed
with ice-cold PBS, collected by scraping with a rubber policeman,
and lysed in 100 ll of ice-cold RIPA buﬀer (50 mM Tris–HCl, pH
8.0, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% so-
dium dodecyl sulfate (SDS), 0.5 mM PMSF, 1 lg/ml aprotinin, 1 lg/
ml leupeptin, 1 lg/ml pepstatin). For CKII activity assay, cells were
disrupted in lysis buﬀer (50 mM Tris–HCl, pH 8.0, 20 mM NaCl,
1 mM MgCl2, 1 mM EDTA, 1% Nonidet P-40, 0.5 mM PMSF, 1 lg/
ml aprotinin, 1 lg/ml leupeptin, 1 lg/ml pepstatin, 1 mM sodium
orthovanadate, 1 mM sodium pyrophosphate, and 4 mM p-nitro-
phenyl phosphate) by sonication. For immuno-blotting and CKII
activity assay with rat tissues, rat livers and testes were homogenized
in RIPA buﬀer or lysis buﬀer using a Dounce homogenizer and a soni-
cator on ice. The particulate debris was removed by centrifugation at
12000 · g for 10 min. Protein concentration in the supernatants was
determined using Bradford protein dye reagent (Bio-Rad, CA), and
the volumes of the supernatants were adjusted for equal protein con-
centration.
2.4. CKII activity assay
The standard assay for phosphotransferase activity of CKII was
conducted in a reaction mixture containing 20 mM Tris–HCl, pH
7.5, 120 mM KCl, 10 mMMgCl2, and 100 lM [c-
32P]GTP in the pres-
ence of 1 mM synthetic peptide substrate (RRREEETEEE) in a total
volume of 30 ll at 30 C. The reactions were started by the addition
of cell lysates and incubated for 15 min. The reaction was stopped
by the addition of trichloroacetic acid to a ﬁnal concentration of
10% and centrifuged, and 10 ll of supernatant was then applied to
P-81 paper. The paper was washed in 100 mM phosphoric acid and
the radioactivity was measured by scintillation counting.
2.5. Immuno-blotting
Proteins were separated on 12% polyacrylamide gel in the presence
of SDS, and then transferred by electrophoresis to nitrocellulose mem-
branes. The membrane was blocked with 5% (w/v) non-fat, dry skim
milk in TBST (20 mM Tris–HCl, pH 7.4, 150 mM NaCl, 0.05% Tween20) for 2 h and then incubated with speciﬁc antibodies in 1% (w/v) non-
fat, dry skim milk for 1 h. The membrane was washed 3 times in TBST,
and then treated with ECL system (Amersham Pharmacia Biotech,
Korea). Some membranes were stripped in stripping buﬀer (2% SDS,
100 mM b-mercaptoethanol, and 50 mM Tris–HCl, pH 7.0) at 50 C
for 1 h with gentle shaking and reprobed with anti-b-actin antibody
as a control for protein loading. Anti-CKIIa and -CKIIb antibodies
were from Calbiochem Co., CA. Anti-p53, -p21Waf-1, and -b-actin anti-
bodies were from Santa Cruz Biotechnology Inc., CA.
2.6. Reverse transcription-polymerase chain reaction
Total RNA was extracted from IMR-90 cells. RNA was reverse
transcribed using gene-speciﬁc reverse primers and reverse transcrip-
tase (Takara, Japan), and resulting cDNAs were polymerase chain
reaction (PCR)-ampliﬁed. PCR primer sequences for CKIIa used
were: CKIIaFwd (5 0-GACAAGCTTATGTCGGGACCC-3 0) and
CKIIaRev (5 0-GACAAGCTTTTACTGCTGAGC-3 0). PCR primer
sequences for CKIIb used were: CKIIbFwd (5 0-GAC-
AAGCTTATGAGCAGCTCAG-30) and CKIIbRev (5 0-GAC-
AAGCTTTCAGCGAATCGTC-30). Primers to b-actin RNA were
used to standardize amounts of RNA in each sample. PCR products
were resolved on a 1.5% agarose gel. Quantiﬁcation of the RT-PCR
bands was performed by using densitometry.
2.7. RNA interference
The anti-CKIIa siRNA used was 5 0-UCAAGAUGACUACCAG-
CUGdTdT. The negative control siRNA was 5 0-GCUCAGAU-
CAAUACGGAGAdTdT [30]. Both siRNAs were applied into the
transfection using Lipofectamin (Invitrogene, CA) as described by
the manufacturer. At 5 h after the transfection, the medium was
changed and the cells were grown for another 3 days before harvesting
or b-gal staining.
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3.1. Decrease in CKII activity in IMR-90 cells during replicative
and H2O2-induced senescence
To determine if CKII activity in IMR-90 cells decreased
progressively during replicative senescence, we repeatedly
passed IMR-90 cells until the senescence-like property was
observed, as determined by morphology, biochemical mark-
ers, and cell doubling time [20]. When diﬀerently passed
IMR-90 cells were stained for SA-b-gal, most of cells at a
PDL 56 stained positive for SA-b-gal, although only rare
cells were found to stain for SA-b-gal in early passage
(PDL 30) cells (Fig. 1A). The phosphotransferase activity
of CKII in extracts of diﬀerently passaged cells was deter-
mined. Unlike other protein kinases, CKII can utilize GTP
instead of ATP as the phosphate donor [31], so CKII activity
was assessed using [c-32P]GTP and the synthetic peptide sub-
strate RRREEETEEE. As shown in Fig. 1B, the repeated
passage of IMR-90 cells resulted in passage-dependent de-
crease of CKII activity.
We next examined if CKII activity decreased in H2O2-in-
duced prematurely senescent IMR-90 cells. Four days after
exposure to 100–400 lM H2O2, IMR-90 cells at a PDL 33Fig. 2. Decrease in CKII activity in IMR-90 cells during H2O2-
induced premature senescence. (A) IMR-90 cells (PDL 33) were seeded
at 1 · 105 cells in 100 mm dishes and treated with H2O2 at 37 C for
2 h. After removing H2O2 by changing medium, the cells were
incubated in fresh culture medium for 4 days and stained with 5-
bromo-4-chloro-3-indolyl b-D-galactoside as described in Section 2.
(B) Lysates from H2O2-treated IMR-90 cells were utilized in kinase
assays using the speciﬁc CKII substrate peptide. The 32P incorporation
in the substrate peptide was measured by scintillation counting. The
results represent two independent experiments done in duplicate.
Results are shown as the mean value ± S.D.exhibited a senescence phenotype, including a ﬂattened and en-
larged morphology [21]. SA-b-gal staining in these cells was in-
creased in a dose-dependent manner by treatment with H2O2
(Fig. 2A). When CKII activity in these cells was assessed using
[c-32P]GTP and CKII peptide substrate, the acceleration of
senescence by H2O2 treatment resulted in dose-dependent inhi-
bition of CKII activity in IMR-90 cells (Fig. 2B). These results
indicate that CKII activity decreases in IMR-90 cells during
both replicative and H2O2-induced senescence.
3.2. Decrease of CKIIa mRNA and protein levels in IMR-90
cells during replicative and H2O2-induced senescence
To determine if reduction in CKII activity in senescent
IMR-90 cells was due to reduced levels of CKII protein, total
protein was extracted from senescent IMR-90 cells (PDL 56)
as well as proliferating IMR-90 cells (PDL 33) that were either
untreated or treated with H2O2. We then analyzed the protein
levels of CKIIa and CKIIb by immuno-blot using anti-CKIIa
and anti-CKIIb antibodies. The protein level of b-actin was
measured as a control. As shown in Fig. 3A, the protein level
of CKIIa decreased in a dose-dependent manner in H2O2-
treated cells and it decreased more signiﬁcantly in senescent
IMR-90 cells (PDL 56). However, the protein level of CKIIb
was not changed in H2O2-treated cells whereas it was reduced
slightly in replicative senescent cells. These results indicate that
the protein level of CKIIa decreases in IMR-90 cells during
both replicative and H2O2-induced premature senescence.
To examine whether this decrease in the amount of CKIIa
protein correlates with a decrease at the RNA level, we
extracted total RNA from IMR-90 cells. We then reverse-Fig. 3. Decrease of CKIIa protein and mRNA levels in IMR-90 cells
during replicative and H2O2-induced senescence. (A) Cells were lysed,
and subjected to electrophoresis on a 12% (w/v) SDS–polyacrylamide
gel, and visualized by immuno-blotting with anti-CKIIa and anti-
CKIIb antibodies. (B) Total RNA was extracted from IMR-90 cells
and reverse transcribed using CKIIa- or CKIIb-speciﬁc primers and
reverse transcriptase. Primers to b-actin RNA were used as a control.
PCR products were resolved on a 1.5% (w/v) agarose gel.
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primers for the human CKIIa and CKIIb. Level of b-actin
mRNA was measured as a control. We observed a signiﬁcant
decrease in the amount of CKIIa mRNA in both H2O2-in-
duced and replicative senescent cells (Fig. 3B). Similar to the
case of CKIIb protein, the CKIIb mRNA level was unchanged
during H2O2-induced senescence whereas it was slightly down-
regulated during replicative senescence. Taken together, these
results indicate that the expression of the CKIIa gene is down-
regulated at transcription level during both replicative and
H2O2-induced senescence in IMR-90 cells.
3.3. Induction of senescence by CKII inhibitors DRB and
apigenin
To investigate if senescence could be induced in response to
CKII inhibitors, young (PDL 30) IMR-90 cells were cultured
in the presence of 10–30 lM DRB for 6 days and then stained
for SA-b-gal activity. SA-b-gal staining in cells tended to be an
increase in a dose-dependent manner by treatment with DRB
(Fig. 4A). When 30 PDL of IMR-90 cells were treated with
30 lM DRB for up to 6 days, a time-dependent increase of
SA-b-gal staining was observed (Fig. 4B). 30 PDL of IMR-
90 cells treated with another CKII inhibitor apigenin exhibited
a higher rate of SA-b-gal staining compared with control cells.
The increase rates in SA-b-gal staining from control were
approximately 10-fold for 20 lM apigenin (Fig. 4C). In con-
trast, serum-starved quiescent cells did not exhibit SA-b-galFig. 4. Induction of senescence by CKII inhibitors. (A) IMR-90 cells were t
cells were treated with 30 lM DRB for 0–6 days. (C) IMR-90 cells were trea
and stained with 5-bromo-4-chloro-3-indolyl b-D-galactoside as described in S
SDS–polyacrylamide gel, and visualized by immuno-blot with anti-p53 andstaining (data not shown). Because SA-b-gal activity, detect-
able at pH 6.0, has been found to be expressed in senescent hu-
man ﬁbroblasts but not in presenescent or quiescent cells [27],
these results indicate that treatment with CKII inhibitor in-
duces a senescence-like phenotype.
We examined if these CKII inhibitor-treated cells would dis-
play other senescent characteristics. The activation of p53 and
p21Waf-1 is essential for cells to establish and maintain cellular
senescence [24,28]. Therefore, we examined whether p53 and
p21Waf-1 would be overexpressed in IMR-90 cells treated with
CKII inhibitors. When the protein levels of p53 and p21Waf-1
were determined by immuno-blot, expression of both proteins
was upregulated in CKII inhibitor-treated cells, like in H2O2-
induced senescent cells (Fig. 4D). Taken together, these results
indicate that inhibition of CKII activity by exogenously added
CKII inhibitors can induce premature senescence of IMR-90
cells.
3.4. Induction of senescence by siRNA against CKIIa
To conﬁrm the role of CKII in cellular senescence, we
knocked down CKIIa in IMR90 cells (PDL 33) by gene silenc-
ing using siRNA duplexes derived from the human CKIIa se-
quence. As shown in Fig. 5A, transfection of anti-CKIIa
siRNA for 3 days markedly reduced the protein level of CKIIa
in IMR-90 cells. However, a control siRNA did not aﬀect the
CKIIa protein level. The protein level of b-actin was measured
as a control. When CKII activity was assessed usingreated with 10–30 lM of CKII inhibitor DRB for 6 days. (B) IMR-90
ted with 20 lM of CKII inhibitor apigenin for 6 days. Cells were ﬁxed
ection 2. (D) IMR-90 cells were lysed, electrophoresed on a 12% (w/v)
anti-p21Waf-1 antibodies.
Fig. 5. Induction of senescence by siRNA against CKIIa. IMR-90
cells (PDL 33) were transfected with either anti-CKIIa or control
siRNAs using Lipofectamin as described by the manufacturer. At 5 h
after the transfection, the medium was changed and the cells were
grown for another 3 days. (A) IMR-90 cells were lysed, electropho-
resed on a 12% (w/v) SDS–polyacrylamide gel, and visualized by
immuno-blot with anti-CKIIa and -b-actin antibodies. (B) Lysates
from IMR-90 cells were utilized in kinase assays using the speciﬁc
CKII substrate peptide. The 32P incorporation in the substrate peptide
was measured by scintillation counting. The results represent two
independent experiments done in duplicate. Results are shown as the
mean value ± S.D. (C) Cells were ﬁxed and stained with 5-bromo-4-
chloro-3-indolyl b-D-galactoside as described in Section 2. The
percentage of positively stained cells was measured.
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that were transfected with anti-CKIIa siRNA contained less
than 40% of CKII activity in the control extract (Fig. 5B).
To assess the knockdown eﬀect on senescence, after transfec-
tion for 3 days the transfectants were then stained for SA-b-gal
activity. 33 PDL of IMR-90 cells transfected with anti-CKIIa
siRNA exhibited a higher rate of SA-b-gal staining compared
with control cells. The increase rate in SA-b-gal staining from
control was approximately 15-fold for CKIIa siRNA. These
results indicate that senescence can be induced by the silencing
of CKIIa gene.
3.5. Decrease of CKII activity and protein levels in tissues from
aged rats
We determined if CKII activity was also decreased by senes-
cence in rat tissues. As shown in Fig. 6A and B, CKII activity
was decreased in the rat liver and testis with advancing age of
the animals. The CKII activity in the liver and testis of 24-
month-old rats was decreased by 50% and 20%, respectively,
over their 6-month-old counterparts. To determine if the
age-related reduction in CKII activity in rat tissues could be
due to reduced levels of CKII protein, the relative protein lev-
els of CKIIa and CKIIb were analyzed by Western blot. As
shown in Fig. 6C, in the rat liver (upper panel) the protein lev-
els of CKIIa were constant, while that of CKIIb reduced withadvancing age. In the rat testes (lower panel in Fig. 6C), how-
ever, the protein levels of CKIIa as well as CKIIb reduced sig-
niﬁcantly with advancing age. These results indicate that the
activity and proteins of CKII is downregulated during aging
in rat tissues. In addition, the present study suggests that
although molecular mechanism for CKII downregulation
could be diﬀerent in diﬀerent tissues, CKII activity downregu-
lation might be a universal phenomenon during organism
aging.4. Discussion
The present results demonstrate that CKII activity is re-
duced during cellular senescence in IMR-90 cells and in rat tis-
sues. The apparent inverse relationship between CKII activity
and PDL of IMR-90 cells or rat age suggests that the decrease
of CKII activity may be tightly coupled to the aging process.
The notion that downregulation of CKII might be linked to
senescence was supported by the observation that exogenously
added CKII inhibitors or anti-CKIIa siRNA could induce
senescent phenotypes of IMR-90 cells. The present results sug-
gest that the age-associated decrease of CKII activity is mainly
regulated at the transcriptional level. CpG islands, which are
possible targets for DNA methylation, exist both around the
exon 1 of the CKIIa gene and in the promoter region of the
CKIIb gene [32,33]. Studies to test whether DNA methylation
is involved in inactivating CKII in senescent cells are in pro-
gress. However, the possibility that CKII activity may be mod-
ulated at translational level and/or by post-translational
modiﬁcation cannot be excluded.
It has been previously reported that polyamine depletion by
treatment with inhibitors of ornithine decarboxylase, which is
the key enzyme in the biosynthesis of polyamines, results in
phenotypic changes associated with cell senescence such as in-
creased cell size and expression of the senescence marker SA-b-
gal [34]. Because overexpression of ornithine decarboxylase
leads to activation of CKII in Balb/MK epidermal cells [35],
the present study suggest that the senescence induction by
polyamine depletion [34] may be mediated in part by CKII-
dependent mechanisms.
How can CKII downregulation induce cellular senescence?
First, CKII is required for cell cycle progression in both G1
and G2/M phases of the cell cycle and that CKII causes the
phosphorylation of several proteins that are necessary for
DNA replication and transcription [1–3,16–19]. Since the hall-
mark of cellular senescence is the failure of senescent cells to
enter the S phase of the cell cycle [20], we speculate that the
underlying cause of aging may be related to alterations of
CKII-mediated phosphorylation of proteins that are involved
in DNA replication. Another possible explanation is that
downregulation of CKII may be involved in the structural
alteration of chromatin. The gradual loss of heterochroma-
tin-induced gene silencing could change gene expression that
is closely linked with aging [36]. In addition, a distinctive type
of heterochromatin has been observed in senescent cells [37].
Since CKII associates preferentially with chromatin and nucle-
ar matrix [38,39], downregulation of CKII might induce per-
turbation of chromatin structure and alteration of gene
silencing, causing cellular senescence. Based on the results pre-
sented here and on previous ﬁndings, we propose that decrease
of CKII activity may cause a defect in the DNA replication
Fig. 6. Decrease of CKII activity and protein levels in tissues from aged rats. Lysates from liver (A) and testis (B) of 6-, 12-, 18-, and 24-month-old
rats were utilized in kinase assays using the speciﬁc CKII substrate peptide. The 32P incorporation in the substrate peptide was measured by
scintillation counting. The results represent two independent experiments done in duplicate. Results are shown as the mean value ± S.D. (C)
Immuno-blot showing changes in CKII protein levels in liver (upper panel) and testis (bottom panel) of aging rats. Liver and testis lysates from 6-,
12-, 18-, and 24-month-old rats were separated on a 12% (w/v) SDS–polyacrylamide gel and visualized by immuno-blot with anti-CKIIa and anti-
CKIIb antibodies.
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cence.
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